Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 333

1.

Sirolimus-based immunosuppression after cardiac transplantation: predictors of recovery from calcineurin inhibitor-induced renal dysfunction.

Gustafsson F, Ross HJ, Delgado MS, Bernabeo G, Delgado DH.

J Heart Lung Transplant. 2007 Oct;26(10):998-1003.

PMID:
17919619
2.

Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.

Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA.

Transplant Proc. 2010 Mar;42(2):542-4. doi: 10.1016/j.transproceed.2010.01.022.

PMID:
20304188
3.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
4.

Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.

Stephany BR, Boumitri M, Budev M, Alao B, Poggio ED.

J Heart Lung Transplant. 2009 Jun;28(6):564-71. doi: 10.1016/j.healun.2009.03.010.

PMID:
19481016
5.

Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.

Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS.

J Heart Lung Transplant. 2005 Dec;24(12):2129-36.

PMID:
16364861
6.

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA.

Liver Transpl. 2007 Dec;13(12):1694-702.

7.

Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.

De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.

Liver Transpl. 2009 Oct;15(10):1262-9. doi: 10.1002/lt.21827.

8.

Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.

Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.

Transplantation. 2007 Aug 27;84(4):467-74.

PMID:
17713429
9.

Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation.

Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ.

J Heart Lung Transplant. 2005 Nov;24(11):1863-7. Epub 2005 Jun 13.

PMID:
16297793
10.
11.

Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus.

Bäckman L, Reisaeter AV, Wramner L, Ericzon BG, Salmela K, Brattström C.

Clin Transplant. 2006 May-Jun;20(3):336-9.

PMID:
16824151
12.

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction.

Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM.

Am J Transplant. 2004 Nov;4(11):1869-75.

13.

Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.

Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.

Clin Transplant. 2004;18 Suppl 12:61-6.

PMID:
15217410
14.

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF; Sirolimus CONVERT Trial Study Group.

Transplantation. 2009 Jan 27;87(2):233-42. doi: 10.1097/TP.0b013e3181927a41.

PMID:
19155978
15.

Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.

Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.

Transplant Proc. 2009 Mar;41(2):756-63. doi: 10.1016/j.transproceed.2009.01.044.

PMID:
19328973
16.

Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.

Cotterell AH, Fisher RA, King AL, Gehr TW, Dawson S, Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Shiffman ML, Posner MP.

Clin Transplant. 2002;16 Suppl 7:49-51.

PMID:
12372044
17.

Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.

Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J.

Transplant Proc. 2009 Dec;41(10):4138-46. doi: 10.1016/j.transproceed.2009.08.065.

PMID:
20005355
18.

Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.

Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A.

Transplant Proc. 2012 Nov;44(9):2564-6. doi: 10.1016/j.transproceed.2012.09.045.

PMID:
23146455
19.

Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.

DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G.

Liver Transpl. 2008 May;14(5):651-9. doi: 10.1002/lt.21429.

20.

Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.

Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.

Transplantation. 2010 Apr 15;89(7):864-72. doi: 10.1097/TP.0b013e3181cbac2d.

PMID:
20061999

Supplemental Content

Support Center